泽璟制药：注射用ZG006与依托泊苷及顺铂联用获得药物临床试验批准

Core Viewpoint - Zai Lab has received approval from the National Medical Products Administration for clinical trials of ZG006 in combination with etoposide and cisplatin for advanced neuroendocrine carcinoma, marking a significant milestone for the company's innovative drug development [1][2]. Group 1: Drug Development - ZG006 (INN: alveltamig) is a trispecific antibody drug developed through the company's dual/multi-specific antibody platform, which has received clinical trial approvals from both the FDA and NMPA [1]. - ZG006 has been designated as a breakthrough therapy by the NMPA and has received orphan drug designation from the FDA, highlighting its potential in treating rare diseases [1]. - ZG006 is the first-in-class molecule targeting DLL3, with the potential to become a best-in-class therapy due to its unique mechanism of action [1]. Group 2: Mechanism of Action - ZG006 binds to different DLL3 epitopes on tumor cells and the CD3 region on T cells, effectively bridging the two and enhancing T cell-mediated tumor cell destruction [2]. - Preclinical studies have demonstrated significant tumor suppression in mouse models, with a notable proportion of tumors completely regressing, indicating ZG006's strong anti-tumor efficacy [2].